High-performance liquid chromatography assay for moxifloxacin in brain tissue and plasma: Validation in a pharmacokinetic study in a murine model of cerebral listeriosis

Moxifloxacin is a broad-spectrum antibacterial 8-methoxy-fluoroquinolone. in order to evaluate the pharmacokinetic properties of moxifloxacin in mouse plasma and brain tissue,we developed a high-performance liquid chromatography (hplc) method. this study was based on single-drug delivery,intravenously dosed in a central listeriosis murine model. the method employed a reversed-phase lichrospher rp-18 with a precolumn (250 4.6 mm) and a mobile phase composed of a mixture of acetonitrile,methanol,and citric buffer (ph = 3.5) with sodium dodecyl sulfate and tetrabutylammonium bromide. fluorescence detection was performed at an excitation wavelength of 290nm and an emission wavelength of 550nm. the relative standard deviation of intra- and inter-day assays was 10. this validated method led to a short retention time (8.0min) for moxifloxacin. the standard curves were linear from 5250g/l in plasma and from 0.12.5g/g of brain tissue. the limits of quantification were 5g/l in plasma and 0.1g/g in brain tissue. the method enabled the detection of systemic antimicrobial in plasma and in cns in listeria-infected mice. injected moxifloxacin passed through the encephalic barrier within a 30 to 60 min after injection time frame. moxifloxacin pharmacokinetics are modeled in an infected model compared to control mice. © copyright 2012 renaud respaud et al.